Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.
Elias Chandran(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Jennifer L. Marté(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Meghali Goswami(National Institutes of Health), Amy Hankin(National Institutes of Health), Marijo Bilušić(National Institutes of Health), Renee N. Donahue(National Institutes of Health), Jeffrey Schlom(National Cancer Institute), Fatima Karzai(National Institutes of Health), James L. Gulley(National Cancer Institute), Philip M. Arlen(Dana-Farber Cancer Institute), Megan Hausler(National Institutes of Health), William D. Figg(National Cancer Institute), Monique Williams(Center for Cancer Research), Mohammad Atiq(Memorial Sloan Kettering Cancer Center), Helen Owens(National Institutes of Health), William L. Dahut(National Cancer Institute)
Cited by 0
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817